home-hero-image-mobile

Vaccine Innovation. Beyond Convention.

We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella to protect every child born and every adult at risk across the globe.

See Our Mission
Image for Pushing the Boundaries of What's Possible

Pushing the Boundaries of What’s Possible

Despite current efforts, Streptococcus pneumoniae bacteria continues to cause significant global morbidity and mortality, particularly for young children and older adults. This underscores the importance of advancing our potentially best-in-class pneumococcal conjugate vaccines (PCVs), including VAX-31, a 31-valent PCV, and VAX-24, a 24-valent PCV, being studied for the prevention of invasive pneumococcal disease (IPD).

Re-Engineering How Vaccines are Made

We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving robust immunogenicity.

Image for Pushing the Boundaries of What's Possible

Building a Pipeline of High-Fidelity and Broad-Spectrum Vaccines

Our PCV franchise, comprising VAX-31 and VAX-24, has the potential to improve upon existing pneumococcal vaccines, setting a new standard-of-care and raising the bar for immunogenicity. Our site-specific, carrier-sparing platform has the potential to deliver the broadest-spectrum PCVs that provide protection against both currently circulating and historically prevalent serotypes. Additional candidates in early-stage development target Group A Strep, periodontitis and Shigella.

Latest News

01

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary  Three-Dose Immunization Series; Topline Results Also Include Interim
02

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow,
03

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and

Careers: Built to Scale with Purpose

Looking for higher aspirations to ignite your mind and inspire your heart? Join a team that brings grit and grace to our mission of protecting humankind from the consequences of bacterial infections.